Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 3/2021

01-03-2021 | Craniopharyngioma | Focus Session

Adamantinomatous craniopharyngioma: advances in proteomic research

Authors: Claudia Desiderio, Diana Valeria Rossetti, Massimo Castagnola, Luca Massimi, Gianpiero Tamburrini

Published in: Child's Nervous System | Issue 3/2021

Login to get access

Abstract

Background

Many efforts have been performed in the last decade to accomplish the genomic and proteomic characterization of pediatric adamantinomatous craniopharyngioma with the purpose to elucidate the molecular mechanisms underlying the onset and development of this pediatric brain tumor, its high recurrence rate, and, although classified as a histologically benign neoplasm, its aggressive behavior.

Methods

The focus of this review is to perform the new comparison of the proteomic profiles of the solid component and the intracystic fluid of adamantinomatous craniopharyngioma based on our previous results, obtained by both the top-down and the bottom-up proteomic approaches, to disclose differences and similarities, and to discuss the results in the context of the most recent literature.

Results and conclusions

Proteins and peptides identified in the cyst fluid and in the solid component of adamantinomatous craniopharyngioma (AC) include beyond markers of inflammation (i.e., alpha-defensins), proteins involved in cell migration and protein degradation (i.e., beta-thymosin and ubiquitin peptides), whose main role might be in tumor growth and infiltration of the surrounding neural structures. These last appeared different in the solid components compared with the cyst fluid, missing their terminal part in the solid tissue, a feature generally associated to malignancies, which might represent a distinct molecular site for an aggressive behavior of AC.
Literature
1.
Massimi L, Martelli C, Caldarelli M, Castagnola M, Desiderio C (2017) Proteomics in pediatric cystic craniopharyngioma. Brain Pathol 27:370–376PubMed
2.
Hengartner AC, Prince E, Vijmasi T Hankinson TC (2020) Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus 48:E7
3.
Whelan R, Prince E, Gilani A, Hankinson T (2020) The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med 9:519PubMedCentral
4.
Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters B, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC, Advancing Treatment for Pediatric Craniopharyngioma Consortium (2017) Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol 76:779–788PubMedPubMedCentral
5.
Iavarone F, Desiderio C, Vitali A, Messana I, Martelli C, Castagnola M, Cabras T (2018) Cryptides: latent peptides everywhere. Crit Rev Biochem Mol Biol 53:246–263PubMed
6.
Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, Cabras T, Messana I, Castagnola M, Di Rocco C (2010) The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst 26:1779–1784PubMed
7.
Desiderio C, Martelli C, Rossetti DV, Di Rocco C, D’Angelo L, Caldarelli M, Tamburrini G, Iavarone F, Castagnola M, Messana I, Cabras T, Faa G (2013) Identification of thymosins β4 and β 10 in paediatric craniopharyngioma cystic fluid. Childs Nerv Syst 29:951–960PubMed
8.
Martelli C, Iavarone F, Vincenzoni F, Rossetti DV, D’Angelo L, Tamburrini G, Caldarelli M, Di Rocco C, Messana I, Castagnola M, Desiderio C (2014) Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down/bottom-up integrated approaches. Electrophoresis 35:2172–2183PubMed
9.
Martelli C, Serra R, Inserra I, Rossetti DV, Iavarone F, Vincenzoni F, Castagnola M, Urbani A, Tamburrini G, Caldarelli M, Massimi L, Desiderio C (2019) Investigating the protein signature of adamantinomatous craniopharyngioma pediatric brain tumor tissue: towards the comprehension of its aggressive behavior. Dis Markers 2;2019:3609789 https://​doi.​org/​10.​1155/​2019/​3609789
10.
Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Suárez C, Genden EM, Rinaldo A, Ferlito A (2012) Craniopharyngioma: a pathologic, clinical, and surgical review. Head Neck 34:1036–1044PubMed
11.
Maneerat Y, Prasongsukarn K, Benjathummarak S, Dechkhajorn W, Chaisri U (2016) Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients. Lipids Health Dis 15:117PubMedPubMedCentral
12.
Ramasundara M, Leach ST, Lemberg DA, Day AS (2009) Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24:202–208PubMed
13.
Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, van ‘t Wout EF, Dean JL, Gray NK, Lu W, Gray M (2016) Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proc Natl Acad Sci U S A 113:4350–4355PubMedPubMedCentral
14.
Hannappel E (2007) Beta-thymosins. Ann N Y Acad Sci 1112:21–37
15.
Goldstein AL, Badamchian M (2004) Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther 4:559–573PubMed
16.
Pardon MC (2018) Anti-inflammatory potential of thymosin β4 in the central nervous system: implications for progressive neurodegenerative diseases. Expert Opin Biol Ther 18(sup1):165–169PubMed
17.
Crockford D, Turjman N, Allan C, Angel J (2010) Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 1194:179–189PubMed
18.
Sanders MC, Goldstein AL, Wang YL (1992) Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci U S A 89:4678–4682PubMedPubMedCentral
19.
Qiu P, Wheater MK, Qiu Y, Sosne G (2011) Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J 25:1815–1826PubMedPubMedCentral
20.
Nemolato S, Restivo A, Cabras T, Coni P, Zorcolo L, Orrù G, Fanari M, Cau F, Gerosa C, Fanni D, Messana I, Castagnola M, Casula G, Faa G (2012) Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. Cancer Biol Ther 13:191–197PubMed
21.
Yu FX, Lin SC, Morrison-Bogorad M, Yin HL (1994) Effects of thymosin beta 4 and thymosin beta 10 on actin structures in living cells. Cell Motil Cytoskeleton 27:13–25PubMed
22.
Kuzan A (2016) Thymosin β as an actin-binding protein with a variety of functions. Adv Clin Exp Med 25:1331–1336PubMed
23.
Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q (2005) Roles of thymosins in cancers and other organ systems. World J Surg 29:264–270PubMed
24.
Goldstein AL (2003) Thymosin beta4: a new molecular target for antitumor strategies. J Natl Cancer Inst 95:1646–1647PubMed
25.
Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C (2009) Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Investig 27:1016–1022
26.
Xiao Y, Chen Y, Wen J, Yan W, Zhou K, Cai W (2012) Thymosin β4: a potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr 22:109–116PubMed
27.
Cha HJ, Jeong MJ, Kleinman HK (2003) Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680PubMed
28.
Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, Chen C, Yao Q, Li M (2008) Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 7:419–423PubMed
29.
Oh SY, Song JH, Gil JE, Kim JH, Yeom YI, Moon EY (2006) ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp Cell Res 312:1651–1657PubMed
30.
Gemoll T, Strohkamp S, Schillo K, Thorns C, Habermann JK (2015) MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer. Oncotarget 6:43869–43880PubMedPubMedCentral
31.
Theunissen W, Fanni D, Nemolato S, Di Felice E, Cabras T, Gerosa C, Van Eyken P, Messana I, Castagnola M, Faa G (2014) Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem 58:2242PubMedPubMedCentral
32.
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin C, Ye L, Zhu J, Li J, Song L, Lin H, He Z (2017) Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res 19:15PubMedPubMedCentral
33.
Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G (2014) Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 137(Pt 2):433–448
34.
Lee JW, Kim HS, Moon EY (2019) Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells. Sci Rep 9:6849PubMedPubMedCentral
35.
Martelli C, Iavarone F, D’Angelo L, Arba M, Vincenzoni F, Inserra I, Delfino D, Rossetti DV, Caretto M, Massimi L, Tamburrini G, Di Rocco C, Caldarelli M, Messana I, Castagnola M, Sanna MT, Desiderio C (2015) Integrated proteomic platforms for the comparative characterization of medulloblastoma and pilocytic astrocytoma pediatric brain tumors: a preliminary study. Mol BioSyst 11:1668–1683PubMed
36.
Rossetti DV, Massimi L, Martelli C, Vincenzoni F, Di Silvestre S, Scorpio G, Tamburrini G, Caldarelli M, Urbani A, Desiderio C (2020) Ependymoma pediatric brain tumor protein fingerprinting by integrated mass spectrometry platforms: a pilot investigation. Cancers (Basel) 12:674
37.
Delfino D, Rossetti DV, Martelli C, Inserra I, Vincenzoni F, Castagnola M, Urbani A, Scarpa S, Fuso A, Cavallaro RA, Desiderio C (2019) Exploring the brain tissue proteome of TgCRND8 Alzheimer’s disease model mice under B vitamin deficient diet induced hyperhomocysteinemia by LC-MS top-down platform. J Chromatogr B Analyt Technol Biomed Life Sci 1124:165–172PubMed
38.
Cabras T, Iavarone F, Martelli C, Delfino D, Rossetti DV, Inserra I, Manconi B, Desiderio C, Messana I, Hannappel E, Faa G, Castagnola M (2015) High-resolution mass spectrometry for thymosins detection and characterization. Expert Opin Biol Ther 15:S191–S201PubMed
39.
Heintz D, Reichert A, Mihelic-Rapp M, Stoeva S, Voelter W, Faulstich H (1994) The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin. Eur J Biochem 223:345–350PubMed
40.
Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD (1999) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5:1424–1427PubMed
41.
Evans MA, Smart N, Dubé KN, Bollini S, Clark JE, Evans HG, Taams LS, Richardson R, Lévesque M, Martin P, Mills K, Riegler J, Price AN, Lythgoe MF, Riley PR (2013) Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nat Commun 4:2081PubMedPubMedCentral
42.
Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM (2011) Protein signatures for survival and recurrence in metastatic melanoma. J Proteome 74:1002–1014
43.
Hegedus CM, Gunn L, Skibola CF, Zhang L, Shiao R, Fu S, Dalmasso EA, Metayer C, Dahl GV, Buffler PA, Smith MT (2005) Proteomic analysis of childhood leukemia. Leukemia 19:1713–1718PubMed
44.
Gonçalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel G, Chabannon C, Extra JM, Viens P, Borg JP, Birnbaum D (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420–1433PubMedPubMedCentral
45.
Laouirem S, Le Faouder J, Alexandrov T, Mestivier D, Léger T, Baudin X, Mebarki M, Paradis V, Camadro JM, Bedossa P (2014) Progression from cirrhosis to cancer is associated with early ubiquitin post-translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy. J Pathol 234:452–463PubMed
46.
Desiderio C, D’Angelo L, Rossetti DV, Iavarone F, Giardina B, Castagnola M, Massimi L, Tamburrini G, Di Rocco C (2012) Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics 12:2158–2166PubMed
47.
Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H (2010) Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 36:201–207PubMed
48.
Ziegler ME, Chen T, LeBlanc JF, Wei X, Gjertson DW, Li KC, Khalighi MA, Lassman CR, Veale JL, Gritsch HA, Reed EF (2011) Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection. Transplantation 92:388–395PubMed
49.
Pimenta DC, Chen VC, Chao J, Juliano MA, Juliano L (2000) Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D. J Protein Chem 19:411–418PubMed
Metadata
Title
Adamantinomatous craniopharyngioma: advances in proteomic research
Authors
Claudia Desiderio
Diana Valeria Rossetti
Massimo Castagnola
Luca Massimi
Gianpiero Tamburrini
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 3/2021
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-020-04750-z

Other articles of this Issue 3/2021

Child's Nervous System 3/2021 Go to the issue

Letter to the Editor

White epidermoid: an important radiological mimic of the dermoid

Case Report

Telescoping flow diverters for a pediatric fusiform distal anterior cerebral artery aneurysm: technical case report

Focus Session

Pediatric low-grade gliomas: molecular characterization of patient-derived cellular models

Original Article

Early de-tethering: analysis of urological and clinical consequences in a series of 40 children

Focus Session

A systematic view of pediatric medulloblastoma proteomics—current state of the field and future directions

Original Article

Genome-wide association study across pediatric central nervous system tumors implicates shared predisposition and points to 1q25.2 (PAPPA2) and 11p12 (LRRC4C) as novel candidate susceptibility loci